Jump: MR Simulation For Radiation Therapy Master Protocol — JUMP  

Prostate Cancer Clinical Trial

Official title: Judging MR Simulation Procedures: A Phase I-II Study of the Use of Magnetic Resonance Imaging Simulation in the Planning of Radiation Treatments

Status Recruiting

Clinical Trial Summary

This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.

Clinical Trial Description

This is a Phase I/II clinical trial. A Phase I clinical trial tests the feasibility and safety of an investigational intervention. "Investigational" means that the process targeting high doses of radiation to the tumor based on MRI is still being studied. This research study is a Feasibility Study, which means it is the first-time investigators at this institution are examining this type of MR-guided dose planning. The U.S. Food and Drug Administration (FDA) has cleared MRI planning for use.

• In Phase I of this study, will prospectively determine the feasibility of using an MRI simulator to plan radiation therapy.

• In Phase II, the efficacy of adjusting RT based on MRI simulation will be explored, either by utilizing an MRI-simulation and synthetic CT to plan treatment or by dose-painting based on functional MRI data ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Head and Neck Cancer
• Head and Neck Neoplasms
• Liver Cancer
• Liver Neoplasms
• Prostate Cancer
• Prostatic Neoplasms
• Recurrent Adenocarcinoma

• NCT number: NCT04545957
• Study type: Interventional
• Source: Dana-Farber Cancer Institute
• Contact: Raymond Mak, MD
• Phone: 617-632-5734
• Email: rmak@partners.org
• Status: Recruiting
• Phase: N/A
• Start date: October 14, 2020
• Completion date: October 22, 2026